about
Role of histone deacetylases in pancreas: Implications for pathogenesis and therapyHistone deacetylase 6 plays a role as a distinct regulator of diverse cellular processesCoadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic BimStructural insights into HDAC6 tubulin deacetylation and its selective inhibitionNEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cellsInhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic modelHistone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation.Advances in epigenetic glioblastoma therapy.Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cellsCrosstalk between HDAC6 and Nox2-based NADPH oxidase mediates HIV-1 Tat-induced pro-inflammatory responses in astrocytes.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.Aggresome formation is regulated by RanBPM through an interaction with HDAC6Cell signalling pathway regulation by RanBPM: molecular insights and disease implications.Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.Paxillin inhibits HDAC6 to regulate microtubule acetylation, Golgi structure, and polarized migration.HDAC6 inhibition restores ciliary expression and decreases tumor growthA novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs.The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties.Misfolded proteins: from little villains to little helpers in the fight against cancer.Differences in microRNA expression during tumor development in the transition and peripheral zones of the prostate.The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulationSyntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.Alteration of histone acetylation pattern during long-term serum-free culture conditions of human fetal placental mesenchymal stem cells.Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cellsMicrotubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules.MicroRNA-26a induced by hypoxia targets HDAC6 in myogenic differentiation of embryonic stem cells.α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration.HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma.Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathwayHistone deacetylase inhibitors: emerging mechanisms of resistance.aPKC phosphorylation of HDAC6 results in increased deacetylation activityHsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsHistone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer.Histone deacetylase 6 associates with ribosomes and regulates de novo protein translation during arsenite stressHistone deacetylase modulators provided by Mother Nature.Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast CancerDual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
P2860
Q26774080-961DCB8C-5AB8-4B38-8C05-FC2712DE5AD0Q26830233-EB447CEC-EF2F-453D-AF58-6037D0AE5C1EQ27322913-601B10A7-024F-4B1E-A6C8-42BBEC3BB886Q27721834-2E9A5FFB-058F-4CA4-B918-A096586494DCQ28308089-6CD1C4D5-A328-482A-9B13-E5FAA4A32B85Q28481142-E218087C-7AEF-4C71-8046-C3A671CF45FEQ28536197-1CF47B2E-9976-4357-987F-006CACCA1F20Q30144009-45EA8A15-8D5D-438B-B973-1BF05B71F8C5Q30570559-BCF86A88-6A6E-49A2-9CDA-06FC812DC19FQ33567030-A34E1335-8DBA-4A44-B41B-BC275FC4C359Q33607294-3DF33A2D-23BC-4280-AFFA-3FFD66E4CBF4Q33676138-DEC92A5D-B88F-4D6B-BA52-580B6605C110Q33703311-F9F4697F-1C38-45AB-8D3B-8E2B05EFA4A8Q33757230-D2A75C75-C47B-4F22-A214-6D329C018565Q33861488-69FF2F95-6109-447E-B5EC-2DE163DFA8B9Q33894574-4B965B6C-C8EE-4C54-90C1-55D3DB4A5B9CQ33959401-0F0BD8B3-C2C8-4885-AA21-6AEB4998F798Q34003129-46AA1E33-9D4F-4890-8E74-85E572EBCD1BQ34035361-D9DCF877-9268-4E10-999E-3EAA27CCCFBBQ34146683-6BBBB81D-2F76-470D-9B9B-CBE58BEFB57CQ34387588-52CB8517-EB8B-4214-8597-DA0E05CD207BQ34466592-E53FB059-F092-4BC4-ABB2-3C7C032055FEQ34868706-55FB3E05-2A60-4491-A8AF-9A3B96B0E0A1Q34984418-4847F932-EBE9-45AF-A105-9B2B8A6F2900Q35044051-7B7119DB-9038-49C1-AB26-3980A04CD07DQ35073567-CAB5F463-D10F-44A6-AAFB-8F4ACA62C67DQ35098895-E0E156AC-F7A4-48AC-A54B-CBD61C8CC9DAQ35116461-687B639D-5FEB-4690-84B2-FE0618634D59Q35131168-2761E133-2DF6-4C90-BB08-E6BA42B10DDDQ35151075-DFB3A7AC-A3F7-460D-8237-A11848A72A5DQ35166324-10A4A9EB-B211-4077-92D9-9B87EE82437CQ35577980-96EC482D-AE84-4C58-84FC-B5C6029D9CDEQ35592607-FBC9B7A3-B73B-4440-9D2D-FDAA6C9CF12DQ35599112-6E344B57-351E-480C-BDEA-65425963073AQ35823157-8ED79570-04A8-4EB7-B996-ED29AFBE9188Q35879608-D311664C-0486-4E3B-8F3D-19B1F436F30EQ35892799-3AA90488-4D97-4EF8-946B-787DE0EA5331Q36049516-602F1383-30FA-40CB-83B2-21E12563548EQ36145714-645D87F7-7C33-4542-B153-D5F914C0E8DDQ36172596-05BD745E-0198-45C9-BCCB-BF4B945ADB79
P2860
description
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The role of HDAC6 in cancer
@ast
The role of HDAC6 in cancer
@en
The role of HDAC6 in cancer
@en-gb
The role of HDAC6 in cancer
@nl
type
label
The role of HDAC6 in cancer
@ast
The role of HDAC6 in cancer
@en
The role of HDAC6 in cancer
@en-gb
The role of HDAC6 in cancer
@nl
altLabel
The Role of HDAC6 in Cancer
@en
prefLabel
The role of HDAC6 in cancer
@ast
The role of HDAC6 in cancer
@en
The role of HDAC6 in cancer
@en-gb
The role of HDAC6 in cancer
@nl
P2860
P3181
P356
P1476
The role of HDAC6 in cancer
@en
P2093
Grace I Aldana-Masangkay
Kathleen M Sakamoto
P2860
P304
P3181
P356
10.1155/2011/875824
P407
P577
2010-11-07T00:00:00Z
2011-01-01T00:00:00Z